# Data Sheet (Cat.No.T68139)



#### Scio-323

#### **Chemical Properties**

CAS No.: 309913-51-7

Formula: C27H30FN3O4

Molecular Weight: 479.54

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

# **Biological Description**

Description	Scio-323 is an orally available p38 mitogen-activated protein (MAPK) kinase inhibitor.
Targets(IC50)	р38 МАРК
In vivo	Oral treatment with the SCIO-323 included delivery for 3 weeks and stopping for 3 weeks, delivery for 3 weeks after an initial 3-week delay, and delivery for 6 weeks continuously. Administration of the SCIO-323 continuously for 6 weeks with/without the presence of particles, or for the initial 3 of 6 weeks had minor effects on bone ingrowth. After establishing a particle-induced chronic inflammatory reaction for 3 weeks, administration of SCIO-323 for a subsequent 3 weeks suppressed net bone formation. The activity of osteoclast-like cells remained low among all treatments when compared with the first control.[1]

### **Solubility Information**

Solubility	DMSO: 27.5 mg/mL (57.35 mM)	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

# **Preparing Stock Solutions**

	1mg	5mg	10mg
1 mM	2.0853 mL	10.4267 mL	20.8533 mL
5 mM	0.4171 mL	2.0853 mL	4.1707 mL
10 mM	0.2085 mL	1.0427 mL	2.0853 mL
50 mM	0.0417 mL	0.2085 mL	0.4171 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

#### Reference

Ma T, et al. Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. J Biomed Mater Res A. 2009;89(1):117-123.



Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com